Two mutant IDH inhibitors, enasidenib (AG-221) and ivosidenib (AG-120), have been approved in ongoing trials on Acute Myeloid Leukemia (AML), and their therapeutic benefits are now studied in other malignancies including CCA [34]. Here, IDH2 is linked to acute myeloid leukemia.